Renal failure fenoldopam

Acute renal failure/microangiopathic hemolytic anemia o Drugs of choice—nicardipine, fenoldopam... 

Landoni G, Biondi-Zoccai GG,Tumlin JA, BoveT, De Luca M, Calabro MG, Ranucci M, and Zangrillo A. 2007. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure a meta-analysis of randomized clinical trials. Am J Kidney Dis 49-56-68. 

Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1996 101 49-53. Madyoon H, Croushore L, Weaver D, Mathur V Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Gather Cardiovasc. Inten/ent 2001 53 341-B. 

V-Ethyl carbamate esters of fenoldopam, used for treatment of acute circulatory failure, provide another example of a carbamate ester prodrug. The intrinsically short half-life and extensive first-pass metabolism of fenoldopam limit its oral administration. /V-Ethyl carbamate esters of fenoldopam provide elevated plasma fenoldopam levels and increases in the renal blood flow of significantly greater duration than when the parent compound is administered orally [30],... 

Peripheral dopaminergic receptor agents are useful in the treatment of congestive heart failure (CHF). Two distinct subtypes of dopamine receptors have been identified. The dopamine (DAi) receptors, which are located on vascular smooth muscles, cause vasodilation in the renal, mesentery, cerebral, and coronary vascular beds (see Figure 49). Thus, the pharmacologic response to activation of the DA2- and DAj-receptor receptors is hypotension, bradycardia, diuresis, and natriuresis. Fenoldopam is an orally active DA -receptor agonist. It is more potent than dopamine in causing... 

---